Omadacycline tosylate |
| Catalog No.GC36805 |
Le tosylate d'omadacycline (PTK 0796), un antibactérien aminométhylcycline actif par voie orale de premier ordre, fait partie de la classe des antibiotiques tétracyclines.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1075240-43-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Omadacycline tosylate is a newly developed aminomethylcycline antibiotic with applications in acute bacterial skin and skin structure infections (ABSSSI) as well as community-acquired bacterial pneumonia (CABP). Derived from minocycline, omadacycline shares similar mechanisms of action with other tetracyclines, inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit. Notably, omadacycline exhibits broad-spectrum antibacterial properties effective against a range of Gram-positive and Gram-negative aerobic, anaerobic, and atypical bacteria[1-4].
Omadacycline tosylate (0.5、2、8、32mg/kg; i.d) has shown strong efficacy in vivo against specific strains of Streptococcus pneumoniae, with bactericidal activity at all experimental doses [5]. Omacycline tosylate (0.25–64 mg/kg) has potent activity against Staphylococcus aureus, including methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) in the neutropenic murine thigh infection model [6]. Mice treated with 15 mg/kg is efficacious in a murine model of pulmonary infection due to M. abscessus. Reduction in the CFU counts of Mycobacteroides abscessus Clinical Isolates in the lungs of mice occurred after 2 weeks of treatment with omadacycline tosylate [7]
References:
[1]. Zhanel GG, Esquivel J, et,al. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. Drugs. 2020 Feb;80(3):285-313. doi: 10.1007/s40265-020-01257-4. PMID: 31970713.
[2]. Gallagher JC. Omadacycline: A Modernized Tetracycline. Clin Infect Dis. 2019 Aug 1;69(Suppl 1):S1-S5. doi: 10.1093/cid/ciz394. PMID: 31367739; PMCID: PMC6669280.
[3]. Watkins RR, Deresinski S. Omadacycline: A Novel Tetracycline Derivative With Oral and Intravenous Formulations. Clin Infect Dis. 2019 Aug 16;69(5):890-896. doi: 10.1093/cid/ciz242. PMID: 30893428.
[4]. Karlowsky JA, Steenbergen J, et,al. Microbiology and Preclinical Review of Omadacycline. Clin Infect Dis. 2019 Aug 1;69(Suppl 1):S6-S15. doi: 10.1093/cid/ciz395. PMID: 31367743; PMCID: PMC6669291.
[5]. Lepak AJ, Zhao M, et,al. In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02368-16. doi: 10.1128/AAC.02368-16. PMID: 28193651; PMCID: PMC5404567.
[6]. Lepak AJ, Zhao M, et,al. In Vivo Pharmacodynamics of Omadacycline against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model. Antimicrob Agents Chemother. 2019 Jun 24;63(7):e00624-19. doi: 10.1128/AAC.00624-19. PMID: 31036691; PMCID: PMC6591633.
[7]. Nicklas DA, Maggioncalda EC, et,al. Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates In Vitro and in a Mouse Model of Pulmonary Infection. Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0170421. doi: 10.1128/AAC.01704-21. Epub 2021 Oct 18. PMID: 34662184; PMCID: PMC8765394.
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *